Zheng Quan Ri Bao·2025-10-30 23:01Core Viewpoint - The company has provided updates on its financial performance and significant corporate actions, including share buybacks, guarantees for subsidiaries, and the impact of legal issues on major shareholders [5][6][10]. Financial Data - The financial statements for the third quarter have not been audited, and the company has reported key financial data and indicators in RMB [3][11]. - The company has acknowledged non-recurring gains and losses, indicating the need for clarity on significant financial items [3]. Shareholder Information - The company has elected a new independent director, effective from July 18, 2025, following a shareholder meeting [5]. - The chairman of the company has initiated a share buyback plan, committing to purchase between RMB 30 million and RMB 60 million worth of shares within a specified timeframe [6]. Corporate Actions - The company has provided a guarantee for its wholly-owned subsidiary, Beihai Pharmaceutical, for a loan of RMB 20 million [7]. - The company has appointed a special auditing firm for a simplified A-share issuance process in 2025 [8]. Investment Returns - The company received a distribution of RMB 3.8037 million from the Huada Gongying No. 1 Fund during the reporting period [9]. Legal Matters - Major shareholders are facing judicial auction of their shares due to a loan dispute, affecting 22,167,585 shares, which represents 4.23% of the company's total equity [10][11].